MetabolicEmerging Evidence

Retatrutide

Also known as: Triple agonist, GIP/GLP-1/Glucagon agonist

Investigational weekly medicine that acts on GIP, GLP-1 and glucagon receptors. It is not FDA-approved and is not available by prescription.

Evidence

Emerging

FDA status

Not FDA-approved

Source

Synthetic triple receptor agonist

Overview

Investigational weekly medicine that acts on GIP, GLP-1 and glucagon receptors. It is not FDA-approved and is not available by prescription.

Mechanism of Action

Tri-agonist activating GIP, GLP-1, and glucagon receptors simultaneously, enhances insulin secretion and suppresses appetite (GIP/GLP-1), increases energy expenditure and fat oxidation (glucagon), studied for weight, blood sugar and liver fat.

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Weight loss in phase 2 and phase 3 trials
  • Increased energy expenditure
  • Enhanced fat oxidation
  • Appetite suppression
  • Improved glycemic control
  • Liver fat (trials)

Researched for

Research topics, not approved uses.

Obesity (investigational)Type 2 diabetes (investigational)Metabolic syndromeWeight management

How Gabriel approaches peptides

Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Retatrutide isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.

Read the peptide therapy guide

Research & Evidence

Evidence Level
Emerging
Studies

Phase 2 trial (NEJM 2023); phase 3 TRIUMPH trials reported in 2026

Summary

A 2023 phase 2 trial reported large weight loss at 48 weeks, and Eli Lilly reported positive phase 3 results in 2026. As of October 2026 it is not FDA-approved; Lilly has said it plans to file for approval in 2027. Products sold online as retatrutide are not the studied medicine.

Safety Information

Potential Side Effects

  • •Nausea
  • •Diarrhea
  • •Vomiting
  • •Constipation

Contraindications

  • Under investigation
  • Likely similar to GLP-1 agonists

Interactions

  • ⚠Under investigation

Quick Facts

CategoryMetabolic
SourceSynthetic triple receptor agonist
StatusInvestigational; not FDA-approved and not available by prescription (as of October 2026)